Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:52:12.553Z.
Calculation as of: 2026-10-06T15:52:12.553Z.
Quote observation: 2026-10-06T15:49:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
MapLight Therapeutics, Inc.
Market Cap
$395.93M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.60M
EV/Sales Ratio
0.62x
TTM Avg
0.69x
3Y Avg
1.51x
5Y Avg
2.02x
Market Cap
$387.27M
EV/Sales Ratio
N/A
TTM Avg
4250.23x
3Y Avg
4250.23x
5Y Avg
4250.23x
Market Cap
$409.58M
EV/Sales Ratio
6.66x
TTM Avg
6.44x
3Y Avg
6.66x
5Y Avg
6.66x
Market Cap
$384.21M
EV/Sales Ratio
0.62x
TTM Avg
0.77x
3Y Avg
0.83x
5Y Avg
0.91x
Market Cap
$412.14M
EV/Sales Ratio
N/A
TTM Avg
0.91x
3Y Avg
12.05x
5Y Avg
12.05x
Market Cap
$380.02M
EV/Sales Ratio
8.88x
TTM Avg
2.21x
3Y Avg
2.18x
5Y Avg
9.49x
Market Cap
$415.78M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $395.93M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $406.60M | 0.62x | 0.69x | 1.51x | 2.02x |
| Carlsmed, Inc. (CARL)vs › | $404.24M | 6.00x | 3.70x | 3.81x | 3.81x |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $387.27M | N/A | 4250.23x | 4250.23x | 4250.23x |
| Shoulder Innovations, Inc. (SI)vs › | $409.58M | 6.66x | 6.44x | 6.66x | 6.66x |
| Orthofix Medical Inc. (OFIX)vs › | $384.21M | 0.62x | 0.77x | 0.83x | 0.91x |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | N/A | 0.91x | 12.05x | 12.05x |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.02M | 8.88x | 2.21x | 2.18x | 9.49x |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.78M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $414.18M | N/A | 403.83x | 403.83x | 403.83x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
